MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Broom sweep clean
Biotech

Novo Nordisk drops 2 obesity drugs during pipeline clearout

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout.
James Waldron Aug 6, 2025 4:44am
liver

Madrigal pens $2B deal for CSPC's GLP-1, eyes Rezdiffra pairing

Jul 30, 2025 7:35am
Fingers crossed

Boehringer 'crossing fingers' ahead of 2 key FDA approvals

Jul 24, 2025 3:00am
Liver

Altimmune stock sinks on mixed ph. 2 MASH results for GLP-1 drug

Jun 26, 2025 8:41am
liver transplant

Rivus weight loss drug shows MASH win, muscle-sparing potential

Jun 24, 2025 10:07am
liver

South Korean biotech's GLP-1 scores MASH win, reduces weight

Jun 16, 2025 7:22am